2.43
price up icon3.85%   0.09
after-market 시간 외 거래: 2.53 0.10 +4.12%
loading
전일 마감가:
$2.34
열려 있는:
$2.34
하루 거래량:
2.76M
Relative Volume:
0.77
시가총액:
$682.59M
수익:
$12.87M
순이익/손실:
$-114.34M
주가수익비율:
-2.8105
EPS:
-0.8646
순현금흐름:
$-79.23M
1주 성능:
-0.41%
1개월 성능:
-12.75%
6개월 성능:
+31.35%
1년 성능:
+12.50%
1일 변동 폭
Value
$2.34
$2.505
1주일 범위
Value
$2.25
$2.505
52주 변동 폭
Value
$1.05
$3.31

Taysha Gene Therapies Inc Stock (TSHA) Company Profile

Name
명칭
Taysha Gene Therapies Inc
Name
전화
(214) 612-0000
Name
주소
3000 PEGASUS PARK DRIVE, DALLAS
Name
직원
73
Name
트위터
Name
다음 수익 날짜
2024-11-12
Name
최신 SEC 제출 서류
Name
TSHA's Discussions on Twitter

TSHA을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
TSHA
Taysha Gene Therapies Inc
2.43 682.59M 12.87M -114.34M -79.23M -0.8646
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-06-27 개시 BMO Capital Markets Outperform
2024-04-09 개시 Piper Sandler Overweight
2023-02-01 다운그레이드 Jefferies Buy → Hold
2023-01-27 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2022-11-09 다운그레이드 Goldman Buy → Neutral
2022-03-09 개시 Robert W. Baird Outperform
2022-03-01 개시 Wells Fargo Overweight
2022-02-18 개시 SMBC Nikko Outperform
2021-12-16 개시 Guggenheim Buy
2021-07-16 개시 Needham Buy
2021-06-24 개시 Truist Buy
2021-06-15 개시 BTIG Research Buy
2021-06-09 개시 Wedbush Outperform
2021-06-08 개시 JMP Securities Mkt Outperform
2021-05-19 개시 Cantor Fitzgerald Overweight
2021-05-11 재개 Jefferies Buy
2021-02-24 개시 William Blair Outperform
2021-01-05 개시 Oppenheimer Outperform
2020-10-19 개시 Chardan Capital Markets Buy
2020-10-19 개시 Goldman Buy
2020-10-19 개시 Jefferies Buy
2020-10-19 개시 Morgan Stanley Overweight
모두보기

Taysha Gene Therapies Inc 주식(TSHA)의 최신 뉴스

pulisher
Jun 14, 2025

Taysha Gene Therapies’ SWOT analysis: promising Rett syndrome therapy boosts stock outlook - Investing.com Australia

Jun 14, 2025
pulisher
Jun 13, 2025

Taysha Gene Therapies price target maintained at $13 by Cantor Fitzgerald - Investing.com Canada

Jun 13, 2025
pulisher
Jun 12, 2025

Taysha gene therapies stock rating reiterated by Cantor Fitzgerald - Investing.com Canada

Jun 12, 2025
pulisher
Jun 11, 2025

Taysha Gene Therapies (TSHA) Price Target Raised Amid High Trial Success Confidence | TSHA Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Adjusts Price Target on Taysha Gene Therapies to $13 From $7, Maintains Overweight Rating - MarketScreener

Jun 11, 2025
pulisher
Jun 10, 2025

Needham Reiterates Buy Rating for Taysha Gene Therapies (TSHA) | - GuruFocus

Jun 10, 2025
pulisher
Jun 06, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Li - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Signify Bio’s $15M round advances in situ protein therapeutics - BioWorld MedTech

Jun 06, 2025
pulisher
Jun 06, 2025

Kalkine: Taysha Gene Therapies Grants Equity Awards to New Joiners – A Closer Look at FTSE 350 Companies' Global Peers - Kalkine Media

Jun 06, 2025
pulisher
Jun 06, 2025

Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 06, 2025
pulisher
Jun 06, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | TSHA Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Taysha Gene Therapies (TSHA) Grants Stock Options to New Employees | TSHA Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Taysha Gene Therapies Grants Stock Options to New Employees Under Inducement Plan - Nasdaq

Jun 06, 2025
pulisher
Jun 06, 2025

Gene Therapy Leader Taysha Awards Massive 401K Share Options Package to Key New Executives - Stock Titan

Jun 06, 2025
pulisher
Jun 05, 2025

Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins - insights.citeline.com

Jun 05, 2025
pulisher
Jun 05, 2025

Taysha Gene Therapies Stock (TSHA): Innovative Gene Therapy Focus - Value The Markets

Jun 05, 2025
pulisher
Jun 04, 2025

Taysha Gene Therapies Releases TSHA-102 Clinical Program Updates - Insider Monkey

Jun 04, 2025
pulisher
Jun 04, 2025

Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Purchased by ProShare Advisors LLC - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

BNP Paribas Financial Markets Acquires New Shares in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Jane Street Group LLC Acquires 62,003 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Taysha Gene Therapies (NASDAQ:TSHA) Given New $11.00 Price Target at Canaccord Genuity Group - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Taysha reports progress in Rett syndrome gene therapy trials By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 03, 2025

Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data By Stocktwits - Investing.com India

Jun 03, 2025
pulisher
Jun 03, 2025

taysha gene therapies increases authorized shares to 700 million By Investing.com - Investing.com Nigeria

Jun 03, 2025
pulisher
Jun 03, 2025

Taysha Gene Therapies (TSHA) Advances TSHA-102 Program for Rett - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Taysha Gene Therapies Announces Details for Oral Presentations a - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Taysha reports progress in Rett syndrome gene therapy trials - Investing.com

Jun 03, 2025
pulisher
Jun 03, 2025

Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program - The Manila Times

Jun 03, 2025
pulisher
Jun 03, 2025

Taysha Gene Therapies Announces Details For Oral Presentations - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program | TSHA Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Taysha Gene Therapies Announces Details for Oral - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

Needham Lifts Taysha Gene Therapies (TSHA) PT to $8, Cites Positive Clinical Data - Insider Monkey

Jun 03, 2025
pulisher
Jun 03, 2025

Taysha Gene Therapies’ (TSHA) Buy Rating Reaffirmed at Needham & Company LLC - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Taysha Gene Therapies (TSHA) Target Price Raised by Canaccord Ge - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Taysha Gene Therapies (TSHA) Price Target Raised by Canaccord | - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

taysha gene therapies increases authorized shares to 700 million - Investing.com

Jun 03, 2025
pulisher
Jun 03, 2025

Taysha Gene Therapies Approves Share Increase Amendment - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

Taysha Gene Therapies (TSHA) Price Target Raised by Canaccord | TSHA Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 02, 2025

Positive Outlook for Taysha Gene Therapies: Buy Rating on Promising TSHA-102 Advancements - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

Taysha Gene Therapies (TSHA) Updates Clinical Progress in Rett S - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Where Taysha Gene Therapies Stands With Analysts - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

Needham Adjusts Taysha Gene Therapies Price Target to $8 From $6, Maintains Buy Rating - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Taysha Gene Therapies (TSHA) Sees Increased Price Target by Needham | TSHA Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Needham Increases Price Target for Taysha Gene Therapies (TSHA) to $8 | TSHA Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Taysha Gene Therapies (TSHA) Price Target Raised by JMP on Positive Rett Syndrome Trial Data - MSN

Jun 02, 2025
pulisher
Jun 02, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Stake Lessened by Deutsche Bank AG - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Bank of America Corp DE Boosts Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World

Jun 01, 2025

Taysha Gene Therapies Inc (TSHA) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
자본화:     |  볼륨(24시간):